Castle Biosciences, Inc.

Castle Biosciences, Inc. is a leading biotechnology company focused on innovative diagnostic tests that drive personalized patient care. Founded in 2008, the company operates from Friendswood, TX, with laboratory facilities in Phoenix, AZ, and Pittsburgh, PA. Castle Biosciences boasts a diverse portfolio of commercial and pipeline tests targeting unmet clinical needs across the patient care continuum. With a strong emphasis on patient benefits, the company's proprietary tests address critical clinical questions and treatment plan challenges in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. The company's flagship product, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that utilizes individual tumor biology to predict metastasis or recurrence risks and sentinel lymph node positivity for invasive cutaneous melanoma. In addition, DecisionDx®-SCC and DecisionDx®-UM offer valuable risk prediction for metastasis in patients with cutaneous squamous cell carcinoma and uveal melanoma, respectively. Furthermore, Castle Biosciences’ comprehensive diagnostic offerings, including myPath® Melanoma and DiffDx®-Melanoma, provide accurate results to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. Notably, TissueCypher® Barrett’s Esophagus represents the world’s first precision medicine test designed to predict the development of esophageal cancer in patients with Barrett’s esophagus. In December 2020, Castle Biosciences secured a substantial $266.80M Post-IPO Equity investment, reflecting investor confidence in the company's growth potential and the value it delivers to patients and healthcare providers through innovative diagnostic solutions. This investment signifies a pivotal moment for the company as it continues to expand its footprint in the healthcare and biotechnology industries. Castle Biosciences remains at the forefront of transforming disease management and improving patient outcomes through its pioneering diagnostic tests.